<DOC>
	<DOCNO>NCT02136017</DOCNO>
	<brief_summary>To evaluate safety post-licensed influenza virus vaccine make Changchun Institute Biological Products Co. , Ltd .</brief_summary>
	<brief_title>Post-License Safety Evaluation Influenza Virus Vaccine</brief_title>
	<detailed_description>In order evaluate safety post-licensed influenza vaccine ( vaccine manufacture Changchun Institute Biological Products Co. , Ltd China ) , retrospectively collect AEFI case report national AEFI surveillance system Sichuan province China 2013 , compare incidence proportion local general reaction , influenza vaccine . Adverse event collect National Immunization Information System 's National Adverse Events Following Immunization ( AEFI ) Surveillance System , establish 2005 basis World Health Organization ( WHO ) guideline . According Guideline Identification Adverse Reaction Immunization issue Chinese Ministry Health 2008 , Sichuan CDC local prefectural CDC must organize expert panel investigate adverse event assess causality , use criterion base Chinese Standard Procedures Vaccination . At time vaccination , vaccinee instruct report adverse event physician vaccination provider . Adverse event fatal result disability cluster event ( i.e. , notably high number similar adverse event related certain vaccine ) require report within 2 hour occurrence . The following adverse event require report within 2 day occurrence : anaphylaxis allergic reaction occur within 24 hour vaccination ; fever ( axillary temperature , &gt; 37.5°C ) , angioedema , local injection-site reaction ( diameter , &gt; 2.5 cm ) occur within 5 day vaccination ; purpura , Arthus reaction , febrile convulsion , seizure , polyneuritis occur within 15 day vaccination ; Guillain-Barré syndrome occur within 3 month vaccination . Other reaction common minor ( e.g. , mild pain fatigue ) require report .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>ever vaccinate one dose influenza vaccine ( manufacture Changchun institute biological product ) 2013 3 year old Severe allergic reaction ( e.g. , anaphylaxis ) previous dose IIV LAIV allergic vaccine component , include egg protein .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>AEFI</keyword>
	<keyword>influenza vaccine</keyword>
</DOC>